Lakefront Biotherapeutics Spotlight: Completed Phase 2 Lupus Study Sets Stage for Key Data Catalyst

Lakefront Biotherapeutics (LKFT) announced an update on their ongoing clinical study.

Lakefront Biotherapeutics (LKFT) has highlighted a completed Phase 2 study run by Galapagos NV on an oral drug called GLPG3667 for adults with active systemic lupus erythematosus. The study, officially titled “A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GLPG3667 in Adult Subjects With Active Systemic Lupus Erythematosus,” aims to show if the drug can safely reduce disease activity and support longer term development in lupus.

The treatment being tested is GLPG3667, also known as Cadefrecitinib, given as an oral capsule once a day. It is designed to control the immune system in lupus, with the goal of lowering flares and improving symptoms while keeping side effects manageable versus standard care.

The trial is an interventional Phase 2 study where patients were randomly assigned to treatment groups, meaning each person had a set chance of getting a specific dose or placebo. It used a double blind setup where patients, doctors, study staff, and outcome assessors did not know who received the active drug, to keep results fair and focused on real treatment effects.

Participants were placed into three groups, including two dose levels of GLPG3667 and one placebo group, all taken orally once daily for 48 weeks. The main purpose of the design is treatment focused, looking at how well the drug works in real patients with active disease while collecting safety data that can guide a larger Phase 3 program.

The study was first submitted on May 3, 2023, which marked the formal launch of the trial process for this lupus program. The most recent update was posted on May 12, 2026, signaling that data cleaning and final reporting steps are active and that the sponsor is preparing the package for broader review.

The status is now listed as completed, indicating that dosing and patient follow up are finished and primary endpoints should be locked. While no results have been posted yet, the timing suggests that topline data could be shared soon, which often acts as a catalyst for both the sponsor and related sector names.

For investors, this update keeps attention on the lupus space, where drugs that offer better safety and convenience than current options can build strong franchises. If GLPG3667 shows solid efficacy and a clean safety profile, it could improve sentiment not only for the originator Galapagos NV but also for LKFT as a peer in immune and inflammation research.

The broader autoimmune field includes competitors with oral and biologic approaches, so investors will watch how GLPG3667 stacks up on response rates and side effects once data are out. Until then, the completed status reduces development risk versus earlier stage projects, but leaves binary data risk in place, which may keep trading ranges tight ahead of any formal readout.

This lupus study of GLPG3667 is completed and recently updated, and further details are available on the ClinicalTrials portal.

To learn more about LKFT’s potential, visit the Lakefront Biotherapeutics drug pipeline page.